Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

8.67EUR
25 May 2018
Change (% chg)

€-0.10 (-1.14%)
Prev Close
€8.77
Open
€8.80
Day's High
€8.82
Day's Low
€8.66
Volume
64,733
Avg. Vol
102,200
52-wk High
€13.68
52-wk Low
€7.65

Select another date:

Fri, May 4 2018

BRIEF-Nicox Q1 Net Revenue At 0.075 Million Euros

* AS OF MARCH 31, 2018, THE GROUP HAD CASH AND CASH EQUIVALENTS OF €36.3 MILLION AS COMPARED WITH €41.4 MILLION AT DECEMBER 31, 2017

BRIEF-Nicox Opening Of U.S. Development Office In Research Triangle Park, North Carolina

* REG-NICOX: OPENING OF U.S. DEVELOPMENT OFFICE IN RESEARCH TRIANGLE PARK, NORTH CAROLINA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Nicox Announces Increase In Royalties From Bausch + Lomb For Vyzulta

* REG-NICOX ANNOUNCES IMPROVED FINANCIAL TERMS FROM BAUSCH + LOMB FOR VYZULTA

BRIEF-Nicox Provides 2018 Outlook And 2017 Estimated Financial Results

* ZERVIATETM (CETIRIZINE OPHTHALMIC SOLUTION), 0.24%, U.S. LAUNCH PLANNED BY PARTNER EYEVANCE PHARMACEUTICALS FOR THE 2018 FALL ALLERGY SEASON

BRIEF-Nicox Updates on Drug Development And Outlines 2018 Activities

* RESOURCES IN 2018 WILL BE FOCUSED ON ADVANCING NICOX'S PIPELINE CANDIDATES NCX 470 AND NCX 4251 TOWARDS MID-STAGE CLINICAL DEVELOPMENT

Select another date: